Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 11, 2021

Affimed Announces Euro25 Million Debt Financing Agreement with Silicon Valley Bank

GlobeNewswire January 11, 2021

Affimed Announces Pipeline and Business Update

GlobeNewswire January 7, 2021

Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating Good Tolerability and a High Objective Response Rate in Patients with Recurrent/Refractory CD30-positive Lymphoma

GlobeNewswire December 7, 2020

Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

GlobeNewswire November 19, 2020

Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress

GlobeNewswire November 10, 2020

Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets

GlobeNewswire November 9, 2020

New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed's AFM13 and Cytokine-Activated Natural Killer Cells

GlobeNewswire November 9, 2020

Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapies

GlobeNewswire November 5, 2020

Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 4, 2020

Affimed to Present at Upcoming Investor Conferences

GlobeNewswire November 4, 2020

Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020

GlobeNewswire November 3, 2020

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

GlobeNewswire October 20, 2020

Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 14, 2020

AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics

GlobeNewswire October 6, 2020

Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination with the Innate Cell Engager AFM13

GlobeNewswire October 6, 2020

Affimed to Present at Jefferies Virtual Cell Therapy Summit

GlobeNewswire September 29, 2020

Affimed to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2020

Affimed Reports Second Quarter 2020 Financial Results and Operational Progress

GlobeNewswire August 11, 2020

Affimed Announces Two New Appointments to Its Supervisory Board

GlobeNewswire August 5, 2020